[
  {
    "trial": "T021",
    "source": "fulltext",
    "arms": {
      "Control group": {"randomized": "105", "analysed": "105"},
      "Racemic ketamine group": {"randomized": "104", "analysed": "104"},
      "High-dose S-ketamine group": {"randomized": "104", "analysed": "104"},
      "Low-dose S-ketamine group": {"randomized": "104", "analysed": "104"}
    },
    "depression": [
      {"measure": "HAMD-17", "day": -1, "form": "mean_sd", "location": "Table 1 (same values in Results, Patients' characteristics)",
       "values": {
         "Control group": {"mean": "15.78", "sd": "4.81", "n": "105"},
         "Racemic ketamine group": {"mean": "16.20", "sd": "4.86", "n": "104"},
         "High-dose S-ketamine group": {"mean": "15.75", "sd": "4.58", "n": "104"},
         "Low-dose S-ketamine group": {"mean": "16.69", "sd": "4.96", "n": "104"}
       }}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "postoperative", "location": "Table 2, 1-month complications ('Dizzy')",
       "values": {
         "Control group": {"dizziness": "12"},
         "Racemic ketamine group": {"dizziness": "13"},
         "High-dose S-ketamine group": {"dizziness": "14"},
         "Low-dose S-ketamine group": {"dizziness": "12"}
       }}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2015-04", "end": "2018-07"},
    "registration": null,
    "note": "Postoperative HAMD-17 and VAS (days 1, 2, 3, 5, 7) appear only in Figures 2 and 1, whose captions print no values, so only baseline HAMD-17 is recorded and pain is empty (Table 1's baseline VAS is not a requested time). Randomized numbers are from Methods; analysed are the table headers, and Results say no patient was lost to follow-up or withdrew. Enrollment dates are from Methods ('enrolled ... from April 2015 to July 2018'); Results give none. Table 2 complications are the 1-month rates; nausea and vomiting are not recorded categories."
  },
  {
    "trial": "T038",
    "source": "registry",
    "arms": {
      "Ketamine Group": {"randomized": "1", "analysed": "1"},
      "Placebo Group": {"randomized": "0", "analysed": "0"}
    },
    "depression": [
      {"measure": "PROMIS Emotional Distress-Depression Short Form", "day": -1, "form": "mean_sd",
       "location": "Posted results, secondary outcome 'Pre-surgical Emotional Distress Related to Depression' (Screening visit)",
       "values": {"Ketamine Group": {"mean": "27", "sd": "0", "n": "1"}, "Placebo Group": {"n": "0"}}},
      {"measure": "PROMIS Emotional Distress-Depression Short Form", "day": 10, "form": "mean_sd",
       "location": "Posted results, secondary outcome 'Post-surgical Emotional Distress Related to Depression' (Day 10-14 Post-Operative Visit)",
       "values": {"Ketamine Group": {"mean": "14", "sd": "0", "n": "1"}, "Placebo Group": {"n": "0"}}},
      {"measure": "PROMIS Emotional Distress-Depression Short Form", "day": 42, "form": "mean_sd",
       "location": "Posted results, secondary outcome 'Post-surgical Emotional Distress Related to Depression' (6-week follow-up visit)",
       "values": {"Ketamine Group": {"mean": "19", "sd": "0", "n": "1"}, "Placebo Group": {"n": "0"}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "overall", "location": "Posted results, adverse events (collected from signed consent to 6 weeks)",
       "values": {"Ketamine Group": {"any_ae": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": null,
    "registration": {"number": "NCT04220489", "date": null},
    "note": "Only one participant enrolled, in the Ketamine Group; the Placebo Group started with 0 (participant flow), so there is no comparison. The registry's 'spread=0' is copied as sd '0' (single participant). Day 10 is the registry's 'Day 10-14 Post-Operative Visit', the average of scores collected POD 10-14. Pain outcomes are only 72-hour summaries (hydromorphone PCA and medical-record opioid use, each 40 mg morphine equivalents per 24 h; VAS 5 averaged over 72 h), so none falls at day 1 or 2; the Pain Catastrophizing Scale had 0 analysed; the cold-pressor test was reported only at screening (19.49, spread 0.98 s). any_ae '0' reads the registry's serious 0/1 and other 0/1 for the Ketamine Group; the Placebo Group's 0/0 had no one at risk and is left out. The registry gives no enrollment dates."
  },
  {
    "trial": "T042",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": null, "analysed": "124"},
      "Control group": {"randomized": null, "analysed": "122"}
    },
    "depression": [
      {"measure": "EPDS", "day": -1, "form": "mean_sd", "location": "Table 1 (same values in Results, first paragraph)",
       "values": {"Esketamine group": {"mean": "3.6", "sd": "3.0", "n": "124"}, "Control group": {"mean": "4.0", "sd": "2.1", "n": "122"}}},
      {"measure": "EPDS", "day": 42, "form": "mean_sd", "location": "Results, first paragraph",
       "values": {"Esketamine group": {"mean": "6.87", "sd": "2.14"}, "Control group": {"mean": "9.02", "sd": "2.21"}}}
    ],
    "pain": [
      {"measure": "NRS at rest", "day": 1, "form": "mean_sd", "location": "Results, NRS at rest sentence (24 h pair)",
       "values": {"Esketamine group": {"mean": "2.86", "sd": "0.58"}, "Control group": {"mean": "3.01", "sd": "0.75"}}},
      {"measure": "NRS at rest", "day": 2, "form": "mean_sd", "location": "Results, NRS at rest sentence (48 h pair)",
       "values": {"Esketamine group": {"mean": "1.91", "sd": "0.62"}, "Control group": {"mean": "2.11", "sd": "0.43"}}},
      {"measure": "NRS on movement", "day": 1, "form": "mean_sd", "location": "Results, NRS on movement sentence (24 h pair)",
       "values": {"Esketamine group": {"mean": "3.39", "sd": "1.57"}, "Control group": {"mean": "4.50", "sd": "0.80"}}},
      {"measure": "NRS on movement", "day": 2, "form": "mean_sd", "location": "Results, NRS on movement sentence (48 h pair)",
       "values": {"Esketamine group": {"mean": "2.43", "sd": "0.87"}, "Control group": {"mean": "3.56", "sd": "0.76"}}},
      {"measure": "cumulative sufentanil consumption 0-24, 24-48, 0-48 h", "day": 1, "form": "mean_sd", "location": "Results, sufentanil sentence ('the first day', 0-24 h)",
       "values": {"Esketamine group": {"mean": "42.5", "sd": "4.58"}, "Control group": {"mean": "50.15", "sd": "5.47"}}},
      {"measure": "cumulative sufentanil consumption 0-24, 24-48, 0-48 h", "day": 2, "form": "mean_sd", "location": "Results, sufentanil sentence ('the second day', 0-48 h)",
       "values": {"Esketamine group": {"mean": "87.40", "sd": "9.51"}, "Control group": {"mean": "95.10", "sd": "9.36"}}}
    ],
    "adverse_events": [
      {"window": "postoperative", "location": "Table 2 (analgesia-related adverse events)",
       "values": {"Esketamine group": {"dizziness": "21"}, "Control group": {"dizziness": "28"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2023-01", "end": "2023-09"},
    "registration": {"number": "ChiCTR2200067054", "date": "2022-12-26"},
    "note": "Per-arm randomized numbers are not printed (360 enrolled; after exclusions, including 29 lost to follow-up, 246 included; Fig. 1 not in text); analysed 124/122 are Table 1's 'Number' row. Day-42 EPDS and all NRS and sufentanil values are text pairs 'X vs. Y'; where the paper names the order (baseline EPDS, sufentanil) esketamine comes first, and the day-42 EPDS and NRS pairs are read the same way, which also fits the stated direction (Fig. 2 and 3 captions). NRS 24 h and 48 h are the 5th and 6th pairs of the rest sentence (2, 4, 8, 12, 24, 48 h). PPD (EPDS >= 13) at day 42 is given only as percentages, '22.2% and 10.7%', said to be esketamine and control 'respectively', which contradicts the same sentence's claim that esketamine was lower; no counts are printed, so there is no count entry. Sufentanil day 2 is the 'second day' figure, which the Fig. 2 caption identifies as 0-48 h; the 24-48 h interval was 43.50 +/- 5.34 vs 46.40 +/- 3.86 ug (esketamine vs control). Dizziness: Table 2 gives control 28 (22.95) and esketamine 21 (16.94), consistent with the arm sizes; the text gives these percentages to the opposite arms; the table is taken. The text places the side effects 'during the surgical procedure', but Methods record them 'throughout PCIA', so postoperative. Enrollment printed as 'January 1, 2023, to September 31, 2023'."
  },
  {
    "trial": "T058",
    "source": "fulltext",
    "arms": {
      "Group S": {"randomized": null, "analysed": "42"},
      "Group C": {"randomized": null, "analysed": "43"}
    },
    "depression": [
      {"measure": "Geriatric Depression Scale (GDS-15)", "day": -1, "form": "mean_sd", "location": "Table 1",
       "values": {"Group S": {"mean": "4.6", "sd": "1.8", "n": "42"}, "Group C": {"mean": "4.6", "sd": "2.0", "n": "43"}}},
      {"measure": "Geriatric Depression Scale (GDS-15)", "day": 2, "form": "mean_sd", "location": "Table 2",
       "values": {"Group S": {"mean": "3.7", "sd": "1.6", "n": "42"}, "Group C": {"mean": "4.7", "sd": "1.6", "n": "43"}}},
      {"measure": "Geriatric Depression Scale (GDS-15)", "day": 2, "form": "count", "definition": "GDS-15 >= 5", "location": "Table 2",
       "values": {"Group S": {"events": "12", "n": "42"}, "Group C": {"events": "23", "n": "43"}}},
      {"measure": "Geriatric Depression Scale (GDS-15)", "day": 7, "form": "mean_sd", "location": "Table 2",
       "values": {"Group S": {"mean": "3.5", "sd": "1.8", "n": "42"}, "Group C": {"mean": "4.3", "sd": "1.7", "n": "43"}}},
      {"measure": "Geriatric Depression Scale (GDS-15)", "day": 7, "form": "count", "definition": "GDS-15 >= 5", "location": "Table 2",
       "values": {"Group S": {"events": "15", "n": "42"}, "Group C": {"events": "21", "n": "43"}}},
      {"measure": "Geriatric Depression Scale (GDS-15)", "day": 30, "form": "mean_sd", "location": "Table 2",
       "values": {"Group S": {"mean": "3.4", "sd": "1.5", "n": "41"}, "Group C": {"mean": "3.3", "sd": "1.6", "n": "41"}}},
      {"measure": "Geriatric Depression Scale (GDS-15)", "day": 30, "form": "count", "definition": "GDS-15 >= 5", "location": "Table 2",
       "values": {"Group S": {"events": "10", "n": "41"}, "Group C": {"events": "9", "n": "41"}}}
    ],
    "pain": [
      {"measure": "worst pain VAS", "day": 1, "form": "median_iqr", "location": "Table 3",
       "values": {"Group S": {"median": "2", "q1": "1", "q3": "3", "n": "42"}, "Group C": {"median": "2", "q1": "1", "q3": "3", "n": "43"}}},
      {"measure": "worst pain VAS", "day": 2, "form": "median_iqr", "location": "Table 3",
       "values": {"Group S": {"median": "1", "q1": "0.75", "q3": "2", "n": "42"}, "Group C": {"median": "2", "q1": "1", "q3": "3", "n": "43"}}},
      {"measure": "effective PCIA presses", "day": 2, "form": "median_iqr", "location": "Table 3 (no time stated; the PCIA ran 48 h)",
       "values": {"Group S": {"median": "1", "q1": "0", "q3": "2", "n": "42"}, "Group C": {"median": "2", "q1": "1", "q3": "4", "n": "43"}}},
      {"measure": "sufentanil consumption", "day": 2, "form": "mean_sd", "location": "Table 3 (no time stated; the PCIA ran 48 h)",
       "values": {"Group S": {"mean": "89.9", "sd": "17.9", "n": "42"}, "Group C": {"mean": "89.7", "sd": "15.9", "n": "43"}}}
    ],
    "adverse_events": [
      {"window": "overall", "location": "Table 5",
       "values": {"Group S": {"hallucination": "2", "dizziness": "5", "nightmare": "6"}, "Group C": {"hallucination": "3", "dizziness": "3", "nightmare": "5"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2022-07", "end": "2023-08"},
    "registration": {"number": "ChiCTR2200061956", "date": null},
    "note": "90 were randomized in total; per-arm numbers are not printed (Fig. 1 not in text). Analysed 43 (C) and 42 (S); 2 (C) and 1 (S) were lost by day 30, hence 41/41 then. Day-2 GDS-15: the text prints '3.7 +/- 1.63 vs. 4.7 +/- 1.62, P = 0.07', Table 2 prints 3.7 +/- 1.6 vs 4.7 +/- 1.6, P 0.007; the table is taken. Table 3's VAS row is labelled only 'VAS, median (IQR)'; Methods name the outcome 'the worst pain score'. Effective presses and sufentanil consumption carry no time in Table 3; they are put at day 2 because the PCIA (the only sufentanil after surgery) ran 48 h; drop them if a stated window is required. Adverse events have no stated window (the study drug was given only in the 48-h postoperative PCIA). In Table 5 the Nightmares and Pruritus rows are identical (5 (11.9) vs 6 (14.3)), and 5 of 43 would be 11.6%."
  },
  {
    "trial": "T106",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": "50", "analysed": "50"},
      "Control group": {"randomized": "50", "analysed": "50"}
    },
    "depression": [],
    "pain": [
      {"measure": "VAS at rest", "day": 1, "form": "median_iqr", "location": "Table 3",
       "values": {"Esketamine group": {"median": "3", "q1": "3", "q3": "3", "n": "50"}, "Control group": {"median": "3.5", "q1": "3", "q3": "4", "n": "50"}}},
      {"measure": "VAS during movement (coughing/deep breathing)", "day": 1, "form": "median_iqr", "location": "Table 3",
       "values": {"Esketamine group": {"median": "3", "q1": "3", "q3": "4", "n": "50"}, "Control group": {"median": "4", "q1": "3", "q3": "4", "n": "50"}}},
      {"measure": "hydromorphone intake", "day": 1, "form": "median_iqr", "location": "Table 3 (24 h after surgery)",
       "values": {"Esketamine group": {"median": "5", "q1": "4", "q3": "5", "n": "50"}, "Control group": {"median": "5", "q1": "4.5", "q3": "5", "n": "50"}}},
      {"measure": "hydromorphone intake", "day": 2, "form": "median_iqr", "location": "Table 3 (48 h after surgery)",
       "values": {"Esketamine group": {"median": "9", "q1": "8.5", "q3": "9.5", "n": "50"}, "Control group": {"median": "9", "q1": "8.5", "q3": "10", "n": "50"}}}
    ],
    "adverse_events": [
      {"window": "postoperative", "location": "Table 3, postoperative adverse events",
       "values": {"Esketamine group": {"dizziness": "1", "nightmare": "0"}, "Control group": {"dizziness": "2", "nightmare": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": null,
    "registration": {"number": "ChiCTR2500096036", "date": null},
    "note": "The source calls the arms 'Experimental' (esketamine) and 'Control'; Figure 1's caption says 100 randomized, 50 per arm, none lost, all analysed. HADS-D (preoperative day 1, POD 1, 3, 5) appears only in Figure 4 (median with IQR) with no printed values, so depression is empty. Table 3's 'median (quartile)' values are recorded as median_iqr. Esketamine VAS during movement on POD 1 is printed '3 (3.4)', read as 3 (3,4). Table 3 also shows a stray '3 (3,3)' in the Experimental column of the 'VAS scores for movement' heading row. The Results text cites Table 2 for VAS, but the values are in Table 3. Postoperative delirium (Control 5 (10), Experimental 7 (14)) is not mapped to a category. No enrollment dates given."
  },
  {
    "trial": "T112",
    "source": "fulltext",
    "arms": {
      "Esketamine": {"randomized": "218", "analysed": "207"},
      "Placebo (normal saline)": {"randomized": "217", "analysed": "203"}
    },
    "depression": [
      {"measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)", "day": -1, "form": "median_iqr", "location": "Table 1, preoperative assessment",
       "values": {"Esketamine": {"median": "24", "q1": "23", "q3": "27", "n": "218"}, "Placebo (normal saline)": {"median": "24", "q1": "22", "q3": "27", "n": "217"}}},
      {"measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)", "day": -1, "form": "count", "definition": "severe depressive symptoms, MADRS >= 30", "location": "Table 1; Results 3.1 (22/218 and 22/217)",
       "values": {"Esketamine": {"events": "22", "n": "218"}, "Placebo (normal saline)": {"events": "22", "n": "217"}}},
      {"measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)", "day": 3, "form": "median_iqr", "location": "Table 2, assessments on POD3 (n from the remission and response rows)",
       "values": {"Esketamine": {"median": "15", "q1": "10", "q3": "20", "n": "207"}, "Placebo (normal saline)": {"median": "18", "q1": "15", "q3": "22", "n": "203"}}},
      {"measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)", "day": 3, "form": "count", "definition": "remission, MADRS <= 10 (events are participants in remission)", "location": "Table 2, primary outcome",
       "values": {"Esketamine": {"events": "59", "n": "207"}, "Placebo (normal saline)": {"events": "23", "n": "203"}}},
      {"measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)", "day": 3, "form": "count", "definition": "response, MADRS reduction >= half of baseline (events are responders)", "location": "Table 2, assessments on POD3",
       "values": {"Esketamine": {"events": "89", "n": "207"}, "Placebo (normal saline)": {"events": "35", "n": "203"}}},
      {"measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)", "day": 5, "form": "median_iqr", "location": "Table 2, assessments on discharge (n from the remission and response rows)",
       "values": {"Esketamine": {"median": "14", "q1": "10", "q3": "19", "n": "198"}, "Placebo (normal saline)": {"median": "17", "q1": "13", "q3": "21", "n": "201"}}},
      {"measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)", "day": 5, "form": "count", "definition": "remission, MADRS <= 10 (events are participants in remission)", "location": "Table 2, assessments on discharge",
       "values": {"Esketamine": {"events": "62", "n": "198"}, "Placebo (normal saline)": {"events": "30", "n": "201"}}},
      {"measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)", "day": 5, "form": "count", "definition": "response, MADRS reduction >= half of baseline (events are responders)", "location": "Table 2, assessments on discharge",
       "values": {"Esketamine": {"events": "86", "n": "198"}, "Placebo (normal saline)": {"events": "47", "n": "201"}}},
      {"measure": "PHQ-9", "day": -1, "form": "median_iqr", "location": "Table 1, preoperative assessment",
       "values": {"Esketamine": {"median": "12", "q1": "11", "q3": "14", "n": "218"}, "Placebo (normal saline)": {"median": "12", "q1": "10", "q3": "13", "n": "217"}}},
      {"measure": "PHQ-9", "day": 3, "form": "count", "definition": "PHQ-9 score >= 10", "location": "Table 2, assessments on POD3",
       "values": {"Esketamine": {"events": "52", "n": "207"}, "Placebo (normal saline)": {"events": "81", "n": "203"}}},
      {"measure": "PHQ-9", "day": 5, "form": "count", "definition": "PHQ-9 score >= 10", "location": "Table 2, assessments on discharge",
       "values": {"Esketamine": {"events": "44", "n": "198"}, "Placebo (normal saline)": {"events": "57", "n": "201"}}},
      {"measure": "HADS", "day": -1, "form": "median_iqr", "location": "Table 1, preoperative assessment",
       "values": {"Esketamine": {"median": "22", "q1": "18", "q3": "25", "n": "218"}, "Placebo (normal saline)": {"median": "21", "q1": "17", "q3": "24", "n": "217"}}},
      {"measure": "HADS", "day": 3, "form": "median_iqr", "location": "Table 2, assessments on POD3",
       "values": {"Esketamine": {"median": "16", "q1": "11", "q3": "21"}, "Placebo (normal saline)": {"median": "20", "q1": "16", "q3": "22"}}},
      {"measure": "HADS", "day": 5, "form": "median_iqr", "location": "Table 2, assessments on discharge",
       "values": {"Esketamine": {"median": "17", "q1": "11", "q3": "21"}, "Placebo (normal saline)": {"median": "19", "q1": "15", "q3": "22"}}}
    ],
    "pain": [
      {"measure": "Moderate-to-severe pain (any NRS >=4 within 72 h)", "day": 2, "form": "count", "definition": "NRS pain score > 3, 0–48 h", "location": "Table 2, secondary outcomes (n from column headers)",
       "values": {"Esketamine": {"events": "50", "n": "218"}, "Placebo (normal saline)": {"events": "47", "n": "217"}}},
      {"measure": "Rescue analgesia, 0–48 h", "day": 2, "form": "count", "definition": "rescue analgesia, 0–48 h", "location": "Table 2, secondary outcomes (n from column headers)",
       "values": {"Esketamine": {"events": "58", "n": "218"}, "Placebo (normal saline)": {"events": "59", "n": "217"}}}
    ],
    "adverse_events": [
      {"window": "postoperative", "location": "Table 2, adverse events (CADSS score >= 5); Results 3.4 (19 of 218 vs 4 of 217, first 72 h)",
       "values": {"Esketamine": {"dissociation": "19"}, "Placebo (normal saline)": {"dissociation": "4"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2021-02", "end": "2024-06"},
    "registration": {"number": "NCT04425473", "date": "2020-06-11"},
    "note": "Analysed 207/203 are the day-3 denominators (25 lost to follow-up); Table 2's header says n = 218/217, which the pain and adverse-event rows use, and discharge assessments have 198/201. 'Assessments on discharge' are coded day 5: Methods plan MADRS at 3 and 5 days and bedside interviews 'on days 1, 2, 3, and 5 or at discharge', but median hospital stay was 11 (9-14) vs 12 (9-15) days, so the timing is uncertain. MADRS n at POD3 and discharge come from the MADRS remission and response denominators in the same section. Remission and response counts are participants who improved, not participants with depression; their definitions say so. The text gives day-3 remission as 28.3% (59/207); the table prints 59/207 (28.5). The text's day-3 MADRS IQR is garbled ('15 [10], [11], ... [20]'); the table's 15 (10-20) is taken. HADS is defined as 'Hospital Anxiety and Depression Scale-Depression', but values above 21 (baseline 22 (18-25)) exceed the HADS-D range, so it may be total HADS. 'NRS pain score > 3, 0-48 h' is the source's form of the design's pain measure (which says within 72 h); 'Rescue analgesia, 0-48 h' is a source-named pain measure. Not mapped to categories (esketamine vs placebo): psychotic side effects (4-item BPRS >= 5) 23 vs 25, manic symptoms (YMRS >= 5) 14 vs 11, delirium 4 vs 11, PONV 0-48 h 46 vs 50. Enrollment is the Methods' screening window (major surgery 'between February 19, 2021, and June 20, 2024'). The trial stopped at a prespecified interim analysis (435 of 564 planned)."
  },
  {
    "trial": "T117",
    "source": "fulltext",
    "arms": {
      "Experimental group (esketamine)": {"randomized": "66", "analysed": "65"},
      "Placebo group": {"randomized": "65", "analysed": "65"}
    },
    "depression": [
      {"measure": "MADRS", "day": -1, "form": "median_iqr", "location": "Table 1",
       "values": {"Experimental group (esketamine)": {"median": "25", "q1": "24", "q3": "27", "n": "65"}, "Placebo group": {"median": "24", "q1": "24", "q3": "28", "n": "65"}}},
      {"measure": "MADRS", "day": 1, "form": "difference", "location": "Results 3.1 text (adjusted mean difference, mixed-effects model; Figure 2 prints no values)",
       "estimate": "-1.97", "lower": "-3.505", "upper": "-0.433", "level": "0.95", "scale": "mean_difference",
       "values": {"Experimental group (esketamine)": {"n": "65"}, "Placebo group": {"n": "65"}}},
      {"measure": "MADRS", "day": 1, "form": "count", "definition": "response, >= 50% reduction from baseline MADRS (events are responders)", "location": "Table 2",
       "values": {"Experimental group (esketamine)": {"events": "35", "n": "65"}, "Placebo group": {"events": "17", "n": "65"}}},
      {"measure": "MADRS", "day": 1, "form": "count", "definition": "remission, MADRS <= 10 (events are participants in remission)", "location": "Table 2",
       "values": {"Experimental group (esketamine)": {"events": "22", "n": "65"}, "Placebo group": {"events": "7", "n": "65"}}},
      {"measure": "MADRS", "day": 2, "form": "difference", "location": "Results 3.1 text (adjusted mean difference, mixed-effects model; Figure 2 prints no values)",
       "estimate": "-1.68", "lower": "-3.213", "upper": "-0.141", "level": "0.95", "scale": "mean_difference",
       "values": {"Experimental group (esketamine)": {"n": "65"}, "Placebo group": {"n": "65"}}},
      {"measure": "MADRS", "day": 2, "form": "count", "definition": "response, >= 50% reduction from baseline MADRS (events are responders)", "location": "Table 2",
       "values": {"Experimental group (esketamine)": {"events": "39", "n": "65"}, "Placebo group": {"events": "26", "n": "65"}}},
      {"measure": "MADRS", "day": 2, "form": "count", "definition": "remission, MADRS <= 10 (events are participants in remission)", "location": "Table 2",
       "values": {"Experimental group (esketamine)": {"events": "26", "n": "65"}, "Placebo group": {"events": "15", "n": "65"}}},
      {"measure": "MADRS", "day": 3, "form": "difference", "location": "Results 3.1 text (adjusted mean difference, mixed-effects model; Figure 2 prints no values)",
       "estimate": "-2.046", "lower": "-3.582", "upper": "-0.510", "level": "0.95", "scale": "mean_difference",
       "values": {"Experimental group (esketamine)": {"n": "65"}, "Placebo group": {"n": "65"}}},
      {"measure": "MADRS", "day": 3, "form": "count", "definition": "response, >= 50% reduction from baseline MADRS (events are responders)", "location": "Table 2",
       "values": {"Experimental group (esketamine)": {"events": "48", "n": "65"}, "Placebo group": {"events": "35", "n": "65"}}},
      {"measure": "MADRS", "day": 3, "form": "count", "definition": "remission, MADRS <= 10 (events are participants in remission)", "location": "Table 2",
       "values": {"Experimental group (esketamine)": {"events": "37", "n": "65"}, "Placebo group": {"events": "15", "n": "65"}}},
      {"measure": "PHQ-9", "day": -1, "form": "median_iqr", "location": "Table 1",
       "values": {"Experimental group (esketamine)": {"median": "16", "q1": "14", "q3": "17", "n": "65"}, "Placebo group": {"median": "16", "q1": "14", "q3": "18", "n": "65"}}},
      {"measure": "PHQ-9", "day": 3, "form": "median_iqr", "location": "Table 2",
       "values": {"Experimental group (esketamine)": {"median": "6", "q1": "5", "q3": "8", "n": "65"}, "Placebo group": {"median": "8", "q1": "6", "q3": "12", "n": "65"}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "postoperative", "day": 1, "location": "Table 3 (dizziness, POD 1); Table 2 (CADSS score > 0, POD 1)",
       "values": {"Experimental group (esketamine)": {"dizziness": "7", "dissociation": "1"}, "Placebo group": {"dizziness": "7", "dissociation": "2"}}},
      {"window": "postoperative", "day": 2, "location": "Table 3 (dizziness, POD 2); Table 2 (CADSS score > 0, POD 2)",
       "values": {"Experimental group (esketamine)": {"dizziness": "0", "dissociation": "1"}, "Placebo group": {"dizziness": "0", "dissociation": "1"}}},
      {"window": "postoperative", "day": 3, "location": "Table 3 (dizziness, POD 3); Table 2 (CADSS score > 0, POD 3)",
       "values": {"Experimental group (esketamine)": {"dizziness": "0", "dissociation": "3"}, "Placebo group": {"dizziness": "0", "dissociation": "1"}}},
      {"window": "postoperative", "day": 14, "location": "Table 2 (CADSS score > 0, 2 weeks after surgery)",
       "values": {"Experimental group (esketamine)": {"dissociation": "0"}, "Placebo group": {"dissociation": "0"}}},
      {"window": "postoperative", "day": 30, "location": "Table 2 (CADSS score > 0, 1 month after surgery)",
       "values": {"Experimental group (esketamine)": {"dissociation": "0"}, "Placebo group": {"dissociation": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": null,
    "registration": {"number": "ChiCTR2300078540", "date": null},
    "note": "Randomized 66/65; one esketamine patient was excluded (discharged on POD 1, data lost), so 65/65 analysed. Postoperative MADRS scores are given only as adjusted mean differences (mixed-effects model with random intercepts; negative favours esketamine) in the text; Figure 2 prints no values. Minus signs printed as Unicode hyphens are written '-'. Response and remission counts are participants who improved, not participants with depression; their definitions say so. NRS pain on POD 1-3 is only in Supplementary Table S6, so pain is empty (Table 1 has preoperative NRS > 3 counts only). Adverse events are per assessment day, keyed by 'day'; a participant can appear on several days, so do not sum them. Dissociation is CADSS score > 0. Not mapped (esketamine vs placebo): YMRS >= 5, POD1 4 vs 3, POD2 3 vs 1, POD3 3 vs 1, 2 weeks 3 vs 0, 1 month 2 vs 0; BPRS > 30, POD1 3 vs 4, POD2 1 vs 4, POD3 1 vs 4, 2 weeks 1 vs 1, 1 month 0 vs 3; nausea and vomiting (Table 3). Baseline CADSS not 0 was 4 vs 4 (Table 1). No enrollment dates given."
  },
  {
    "trial": "T118",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": "42", "analysed": "18"},
      "Saline placebo group": {"randomized": "41", "analysed": "17"}
    },
    "depression": [
      {"measure": "MADRS", "day": -1, "form": "mean_sd", "location": "Table 1",
       "values": {"Esketamine group": {"mean": "19.39", "sd": "3.38", "n": "18"}, "Saline placebo group": {"mean": "19.06", "sd": "3.82", "n": "17"}}},
      {"measure": "PHQ-9", "day": -1, "form": "mean_sd", "location": "Table 1",
       "values": {"Esketamine group": {"mean": "10.28", "sd": "2.24", "n": "18"}, "Saline placebo group": {"mean": "9.82", "sd": "2.58", "n": "17"}}}
    ],
    "pain": [],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": null,
    "registration": {"number": "ChiCTR2300071062", "date": null},
    "note": "Secondary neuroimaging analysis of the EASE trial: 83 of 108 eligible RCT patients consented to MRI and were randomized 42 esketamine / 41 placebo; 45 declined the follow-up MRI and 3 were excluded for head motion, leaving 18/17 analysed. MADRS was rated at baseline (day before surgery), PODs 1-5 and weeks 4 and 12, but no postoperative values are printed, only correlations of MADRS change with network measures in the esketamine group. Baseline PHQ-9 is a depression measure the design does not list. The healthy-control group (n = 35) has role 'other' and is left out. No adverse events, pain, or enrollment dates reported."
  },
  {
    "trial": "T123",
    "source": "library",
    "arms": {
      "Esketamine group": {"randomized": "60", "analysed": "57"},
      "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {"randomized": "60", "analysed": "55"}
    },
    "depression": [
      {"measure": "Hamilton Depression Scale (HAMD)", "day": -1, "form": "median_iqr", "location": "Table 1",
       "values": {"Esketamine group": {"median": "4", "q1": "3", "q3": "5.5", "n": "57"}, "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {"median": "5", "q1": "3", "q3": "6", "n": "55"}}},
      {"measure": "Hamilton Depression Scale (HAMD)", "day": 1, "form": "median_iqr", "location": "Table 3",
       "values": {"Esketamine group": {"median": "3", "q1": "2", "q3": "4", "n": "57"}, "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {"median": "4", "q1": "2", "q3": "6", "n": "55"}}},
      {"measure": "Hamilton Depression Scale (HAMD)", "day": 2, "form": "median_iqr", "location": "Table 4, POD two",
       "values": {"Esketamine group": {"median": "2", "q1": "2", "q3": "3", "n": "57"}, "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {"median": "3", "q1": "2", "q3": "4", "n": "55"}}},
      {"measure": "Hamilton Depression Scale (HAMD)", "day": 3, "form": "median_iqr", "location": "Table 4, POD three",
       "values": {"Esketamine group": {"median": "1", "q1": "0.5", "q3": "2", "n": "57"}, "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {"median": "2", "q1": "1", "q3": "2", "n": "55"}}},
      {"measure": "Hamilton Depression Scale (HAMD)", "day": 7, "form": "median_iqr", "location": "Table 4, POD seven",
       "values": {"Esketamine group": {"median": "1", "q1": "0", "q3": "2", "n": "57"}, "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {"median": "1", "q1": "0", "q3": "2", "n": "55"}}}
    ],
    "pain": [
      {"measure": "Number of PCIA attempts within 48 h (sufentanil PCIA)", "day": 2, "form": "median_iqr", "location": "Table 2 ('Number of PCIA Attempt (times)')",
       "values": {"Esketamine group": {"median": "0", "q1": "0", "q3": "2", "n": "57"}, "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {"median": "1", "q1": "0", "q3": "3", "n": "55"}}},
      {"measure": "Rescue analgesics (flurbiprofen axetil) within 48 h", "day": 2, "form": "count", "definition": "received rescue flurbiprofen axetil within 48 h", "location": "Table 2; Results, secondary outcomes (seven of 57 vs 17 of 55)",
       "values": {"Esketamine group": {"events": "7", "n": "57"}, "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {"events": "17", "n": "55"}}}
    ],
    "adverse_events": [
      {"window": "postoperative", "location": "Table 6 (monitored from the start of PCIA to POD 7)",
       "values": {"Esketamine group": {"dizziness": "3", "psychiatric_any": "0"}, "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {"dizziness": "7", "psychiatric_any": "1"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2024-06", "end": "2024-11"},
    "registration": {"number": "ChiCTR2400085319", "date": null},
    "note": "Randomized 60 per group from Methods ('60 participants in each group were enrolled'); Results say 120 randomized and 8 excluded, leaving the per-protocol 57/55 (Figure 1 not in text). The text is a PDF extraction in which Table 2's esketamine column is printed apart from its rows; it was matched by row order (11 rows), which the text's rescue figures (seven of 57 vs 17 of 55, P = 0.016) and the P values confirm. The NRS rows in Tables 3 and 4 sit under 'Subjective sleep quality' and are the sleep NRS (0 = best possible sleep), not pain; postoperative pain NRS values are not printed (Table 1's preoperative pain NRS is 3 (2 to 3) in both groups). PCIA attempts carry no time in Table 2; the PCIA ran 48 h. 'Psychiatric symptoms' (Table 6) is a combined count, so psychiatric_any. Delirium within 3 days (3D-CAM, Table 5) was 8 (14.5) vs 5 (8.8), sufentanil vs esketamine, not mapped. Enrollment is the study period in Methods (June 10 to November 30, 2024), which Results refer to ('during this period')."
  }
]